Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Beigene Ltd ADR (NQ: BGNE )

193.64 -11.40 (-5.56%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 12, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Beigene Ltd ADR

< Previous 1 2
...
10 11 12 13 14 15 16 17 Next >
China NMPA Approves Tislelizumab in Non-Small Cell Lung Cancer and Hepatocellular Carcinoma
From BeiGene, Ltd.
Via Business Wire
A Peek Into The Markets: US Stock Futures Signal Higher Start On Wall Street
Pre-open movers U.S. stock futures traded higher in early pre-market trade after the Dow Jones tumbled more than 500 points in the previous session. The Chicago Fed National... 
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
5 Stocks To Watch For June 21, 2021
Some of the stocks that may grab investor focus today are: Amazon.com, Inc. (NASDAQ: AMZN) will remain in focus with the company’s two-day Prime shopping event beginning... 
Via Benzinga
Week In Review: This Week's China Life Science Deals Total Over $2.5 Billion
Shanghai's Zai Lab announced a four-drug immunonocology deal with MacroGenics ​​​worth over $1.4 billion. Shanghai's HutchMed (formerly Hutchison Chi-Med) is planning to raise $600 million in a Hong... 
Via Talk Markets
BeiGene Announces China NMPA Approval of BRUKINSA® (Zanubrutinib) for the Treatment of Patients with Relapsed or Refractory Waldenström’s Macroglobulinemia
From BeiGene
Via Business Wire
BeiGene Announces First Patient Dosed in Global Phase 3 Trial of Anti-TIGIT Antibody Ociperlimab in Non-Small Cell Lung Cancer
From BeiGene, Ltd.
Via Business Wire
Week In Review: Shanghai CARsgen To Raise $400 Million In Hong Kong IPO
Shanghai CARsgen Therapeutics is staging an IPO on the Hong Kong Exchange that could raise $400 million to support development of the company's CAR-T portfolio. The shares are scheduled to begin... 
Via Talk Markets
Topics Initial Public Offering
Exposures Securities Market
BeiGene Touts Initial Brukinsa Efficacy, Safety Profile For Leukemia, Compared To Imbruvica
BeiGene Ltd (NASDAQ: BGNE) revealed an interim analysis of the Phase 3 ALPINE trial evaluating Brukinsa (zanubrutinib) to Johnson & Johnson’s (... 
Via Benzinga
BeiGene Presents Long-Term Efficacy and Safety Results from Three Pivotal Trials of BRUKINSA® (Zanubrutinib) and Tislelizumab at EHA2021
From BeiGene, Ltd.
Via Business Wire
BeiGene Presents ALPINE Results at EHA2021 Demonstrating Both Efficacy and Safety Advantages of BRUKINSA® (Zanubrutinib) in Head-to-Head Comparison to Ibrutinib in Chronic Lymphocytic Leukemia
From BeiGene, Ltd.
Via Business Wire
BeiGene, Shoreline Biosciences Ink Development Pact For NK Cell Therapies In Cancer
Shoreline Biosciences Inc and BeiGene Ltd (NASDAQ: BGNE) have announced an exclusive worldwide strategic collaboration to develop and commercialize a... 
Via Benzinga
Shoreline Biosciences and BeiGene Announce Strategic Worldwide Collaboration to Develop and Commercialize Genetically Modified Natural Killer (NK) Cell Therapies
From BeiGene, Ltd.
Via Business Wire
The Daily Biotech Pulse: Hookipa, PDS Biotech Report Positive Data, Ironwood CFO To Depart, Decision Day For Vertex
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 7) Agios Pharmaceuticals, Inc... 
Via Benzinga
BeiGene Announces Acceptance of a Supplemental Biologics License Application in China for Tislelizumab in Microsatellite Instability-High (MSI-H) or Mismatch Repair-Deficient (dMMR) Solid Tumors
From BeiGene, Ltd.
Via Business Wire
The Week Ahead In Biotech: Biogen, Alexion And Vertex FDA Decisions, Multiple Conference Presentations On The Deck
Biopharma stocks advanced in the truncated week ended June 4 amid the broader market strength. The American Society for Clinical Oncology meeting got underway during the week,... 
Via Benzinga
Exposures Product Safety
BeiGene Presents Clinical Data from Two Pivotal Trials of Tislelizumab at the 2021 ASCO Annual Meeting
From BeiGene, Ltd.
Via Business Wire
BeiGene Presents Clinical Data from Two Phase 2 Trials of Pamiparib at the 2021 ASCO Annual Meeting
From BeiGene, Ltd.
Via Business Wire
BeiGene Announces First Presentation of the Phase 3 ALPINE Trial Comparing BRUKINSA® (Zanubrutinib) to Ibrutinib in Chronic Lymphocytic Leukemia to Be Featured in Presidential Symposium at EHA2021
From BeiGene, Ltd.
Via Business Wire
Week In Review: LianBio Acquires Two IBD Candidates In $218 Million Deal
LianBio, a Princeton-Shanghai company, in-licensed Greater China rights for two inflammatory bowel disease candidates from Landos Biopharma. The $218 million deal includes $18 million upfront and $200... 
Via Talk Markets
BeiGene's Tislelizumab Shows Progression-Free Survival Benefit in Type Of Head & Neck Cancer
BeiGene Ltd (NASDAQ: BGNE) has announced topline results from the Phase 3 RATIONALE 309 trial evaluating tislelizumab combined with chemotherapy as a... 
Via Benzinga
BeiGene Announces Positive Topline Results from Phase 3 Trial of Tislelizumab in Combination with Chemotherapy as First-Line Treatment for Recurrent or Metastatic Nasopharyngeal Cancer
From BeiGene, Ltd.
Via Business Wire
The Week Ahead In Biotech: ASCO Presentations Front And Center, FDA Decisions Due For Scynexis, Liminal And Alkermes
After having declined through the first half of the week, biotech stocks staged a recovery to close higher in the trading week ended May 28. Broader market sentiment and company-... 
Via Benzinga
Exposures Product Safety
BeiGene to Showcase Broad Clinical Portfolio at 2021 ASCO Annual Meeting
From BeiGene, Ltd.
Via Business Wire
BeiGene's Brukinsa US Application For Expanded Use Under FDA Review
The FDA has accepted for review BeiGene Ltd's (NASDAQ: BGNE) supplemental marketing application for Brukinsa (zanubrutinib) for marginal zone lymphoma (MZL)... 
Via Benzinga
Exposures Product Safety
BeiGene Announces U.S. FDA Acceptance and Priority Review of Supplemental New Drug Application for BRUKINSA® (Zanubrutinib) in Marginal Zone Lymphoma
From BeiGene, Ltd.
Via Business Wire
BeiGene Highlights Progress in Hematology at EHA2021 Virtual Congress
From BeiGene, Ltd.
Via Business Wire
Week In Review: WHO Close To Approving Global Use For Two China COVID-19 Vaccines
The World Health Organization approved Sinopharm's COVID-19 vaccine for emergency use, which will give poorer nations access to a vaccine against the pandemic. Sinovac's inactivated COVID-19 vaccine... 
Via Talk Markets
Exposures COVID-19
China NMPA Approves PARP Inhibitor Pamiparib for Patients with Previously Treated Advanced Ovarian Cancer
From BeiGene, Ltd.
Via Business Wire
BeiGene Reports First Quarter 2021 Financial Results
From BeiGene, Ltd.
Via Business Wire
This Is Why Humira Isn't AbbVie's Biggest Problem Right Now
Two of AbbVie's most important assets could get a lot harder to sell. 
Via The Motley Fool
Topics Intellectual Property
Exposures Intellectual Property
< Previous 1 2
...
10 11 12 13 14 15 16 17 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.